<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2312-3893</journal-id>
<journal-title><![CDATA[Revista Virtual de la Sociedad Paraguaya de Medicina Interna]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. virtual Soc. Parag. Med. Int.]]></abbrev-journal-title>
<issn>2312-3893</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Paraguaya de Medicina Interna]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2312-38932026000100317</article-id>
<article-id pub-id-type="doi">10.18004/rvspmi/2312-3893/2026.e13142617</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Hipertensión arterial pulmonar secundaria a uso de dasatinib]]></article-title>
<article-title xml:lang="en"><![CDATA[Pulmonary arterial hypertension secondary to dasatinib use]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Romero]]></surname>
<given-names><![CDATA[Rolando José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Orlova]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bocci]]></surname>
<given-names><![CDATA[Bruno Daniel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Coyago Bermeo]]></surname>
<given-names><![CDATA[Marco Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pereira Rodríguez]]></surname>
<given-names><![CDATA[Javier Elicer]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barron Sandi]]></surname>
<given-names><![CDATA[Zoraida]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Garrido Hernández]]></surname>
<given-names><![CDATA[Giusti Valeria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales Méndez]]></surname>
<given-names><![CDATA[Eimar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Italiano de Buenos Aires Sede San Justo Departamento de Medicina Interna Servicio de Medicina Interna]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Italiano de Buenos Aires Departamento de Hematología Servicio de Hematología]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital Italiano de Buenos Aires Departamento de Cardiología Servicio de Cardiología]]></institution>
<addr-line><![CDATA[Buenos Aires ]]></addr-line>
<country>Argentina</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro de Estudios e Investigación FISICOL Departamento de Fisiología ]]></institution>
<addr-line><![CDATA[Cúcuta ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2026</year>
</pub-date>
<volume>13</volume>
<numero>1</numero>
<fpage>317</fpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S2312-38932026000100317&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S2312-38932026000100317&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S2312-38932026000100317&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La hipertensión pulmonar es una enfermedad de etiología multifactorial cuyo abordaje diagnóstico y terapéutico depende de la causa subyacente. Dentro de las etiologías menos frecuentes se encuentra la hipertensión arterial pulmonar inducida por fármacos, entre ellos los inhibidores de la tirosina quinasa utilizados en patologías hemato-oncológicas. Se presenta el caso de una paciente femenina de 35 años con antecedente de leucemia mieloide crónica en tratamiento con dasatinib, quien consultó por disnea progresiva. Los estudios iniciales evidenciaron hipertensión pulmonar severa mediante ecocardiograma transtorácico. Se descartó compromiso estructural del corazón izquierdo, enfermedad parenquimatosa pulmonar y tromboembolismo pulmonar. El cateterismo cardíaco derecho confirmó un patrón hemodinámico compatible con hipertensión arterial pulmonar del grupo 1. Ante la ausencia de otras etiologías identificables, se estableció la asociación causal con el uso de dasatinib. Tras la suspensión del fármaco se observó una mejoría clínica y hemodinámica significativa, lo que reforzó el diagnóstico de hipertensión arterial pulmonar inducida por dasatinib. Este caso resalta la importancia del reconocimiento precoz de esta complicación infrecuente, la necesidad de una vigilancia cardiovascular estrecha en pacientes tratados con inhibidores de la tirosina quinasa y el valor de un enfoque multidisciplinario para optimizar el pronóstico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Pulmonary hypertension is a multifactorial disease whose diagnostic and therapeutic approach depends on the underlying cause. Among the less common aetiologies is drug-induced pulmonary arterial hypertension, including tyrosine kinase inhibitors used in haematological and oncological diseases. We present the case of a 35-year-old female patient with a history of chronic myeloid leukaemia undergoing treatment with dasatinib, who consulted for progressive dyspnoea. Initial studies revealed severe pulmonary hypertension by transthoracic echocardiogram. Structural involvement of the left heart, pulmonary parenchymal disease, and pulmonary thromboembolism were ruled out. Right heart catheterization confirmed a haemodynamic pattern consistent with group 1 pulmonary arterial hypertension. In the absence of other identifiable aetiologies, a causal association with dasatinib use was established. After discontinuation of the drug, significant clinical and haemodynamic improvement was observed, reinforcing the diagnosis of dasatinib-induced pulmonary arterial hypertension. This case highlights the importance of early recognition of this rare complication, the need for close cardiovascular monitoring in patients treated with tyrosine kinase inhibitors, and the value of a multidisciplinary approach to optimize prognosis.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[hipertensión pulmonar]]></kwd>
<kwd lng="es"><![CDATA[inhibidor de la tirosina quinasa]]></kwd>
<kwd lng="es"><![CDATA[leucemia mieloide de fase crónica]]></kwd>
<kwd lng="es"><![CDATA[apoptosis]]></kwd>
<kwd lng="en"><![CDATA[pulmonary hypertension]]></kwd>
<kwd lng="en"><![CDATA[tyrosine kinase inhibitor]]></kwd>
<kwd lng="en"><![CDATA[chronic phase myeloid leukaemia]]></kwd>
<kwd lng="en"><![CDATA[apoptosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Humbert]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kovacs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Hoeper]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Badagliacca]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[RMF]]></given-names>
</name>
<name>
<surname><![CDATA[Brida]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2022</year>
<volume>43</volume>
<numero>38</numero>
<issue>38</issue>
<page-range>3618-731</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[El-Dabh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Acharya]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors]]></article-title>
<source><![CDATA[Pulm Circ]]></source>
<year>2019</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weatherald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bondeelle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chaumais]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Ch]]></surname>
<given-names><![CDATA[Guignabert]]></given-names>
</name>
<name>
<surname><![CDATA[Savale]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jaïs]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2020</year>
<volume>56</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>2000279</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kotlyar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Makanji]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[DY]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Casorso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparative adherence to macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension]]></article-title>
<source><![CDATA[J Med Econ]]></source>
<year>2024</year>
<volume>27</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>596-604</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bourne]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatia]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jamy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment-free remission in chronic myeloid leukemia]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2024</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2567</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Weatherald]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chaumais]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Savale]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jaïs]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Seferian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matthieu Canuet]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of dasatinib-induced pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Eur Respir J]]></source>
<year>2017</year>
<volume>50</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1700217</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yurtta&#351;]]></surname>
<given-names><![CDATA[NÖ]]></given-names>
</name>
<name>
<surname><![CDATA[E&#351;kazan]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dasatinib-induced pulmonary arterial hypertension]]></article-title>
<source><![CDATA[Br J Clin Pharmacol]]></source>
<year>2018</year>
<volume>84</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>835-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
